uniQure (NASDAQ:QURE) CEO Sells $1,436,374.32 in Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 28,716 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $50.02, for a total transaction of $1,436,374.32. Following the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at $25,971,734.54. This trade represents a 5.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of uniQure stock opened at $47.51 on Monday. The company’s fifty day simple moving average is $27.84 and its 200-day simple moving average is $23.03. The stock has a market capitalization of $3.00 billion, a PE ratio of -13.65 and a beta of 0.98. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. As a group, equities analysts anticipate that uniQure N.V. will post -3.65 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on QURE shares. Chardan Capital upped their price target on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $25.00 to $65.00 in a research note on Thursday, June 18th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a report on Wednesday, June 17th. Leerink Partners raised their target price on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, Mizuho lifted their price target on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.67.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in QURE. CIBC Private Wealth Group LLC bought a new stake in uniQure during the 3rd quarter valued at approximately $50,000. Torren Management LLC bought a new position in uniQure in the 4th quarter worth approximately $28,000. FNY Investment Advisers LLC grew its holdings in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares in the last quarter. IFP Advisors Inc purchased a new stake in uniQure during the 4th quarter valued at approximately $48,000. Finally, Knott David M Jr bought a new stake in shares of uniQure during the third quarter valued at approximately $117,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.